Limited durability of viral control following treated acute HIV infection

• Published in: PLoS medicine 2004-11, Vol.1 (2), p.e36-e36
• Main Authors: Kaufmann, Daniel E, Lichterfeld, Mathias, Altfeld, Marcus, Addo, Marylyn M, Johnston, Mary N, Lee, Paul K, Wagner, Bradford S, Kalife, Elizabeth T, Strick, Daryld, Rosenberg, Eric S, Walker, Bruce D
• Format: Article
• Language: English
• Subjects: Acquired immune deficiency syndrome; Acute Disease; Adult; AIDS; Antiretroviral Therapy, Highly Active; Drug Administration Schedule; Drug resistance; Drug therapy; Female; HIV; HIV Infection/AIDS; HIV Infections - drug therapy; HIV Infections - virology; HIV-1 - pathogenicity; HIV/AIDS; Human immunodeficiency virus; Humans; Hypotheses; Immune system; Immunology; Immunology and allergy; Infections; Infectious Diseases; Longitudinal Studies; Male; Middle Aged; Plasma; Treatment Outcome; Viremia
• ISSN: 1549-1676; 1549-1277; 1549-1676
• DOI: 10.1371/journal.pmed.0010036

Early treatment of acute HIV infection with highly active antiretroviral therapy, followed by supervised treatment interruption (STI), has been associated with at least transient control of viremia. However, the durability of such control remains unclear. Here we present longitudinal follow-up of a single-arm, open-label study assessing the impact of STI in the setting of acute HIV-1 infection. Fourteen patients were treated during acute HIV-1 infection and subsequently subjected to an STI protocol that required retreatment if viral load exceeded 50,000 RNA copies/ml plasma or remained above 5,000 copies/ml for more than three consecutive weeks. Eleven of 14 (79%) patients were able to achieve viral loads of less than 5,000 RNA copies/ml for at least 90 d following one, two, or three interruptions of treatment. However, a gradual increase in viremia and decline in CD4+ T cell counts was observed in most individuals. By an intention-to-treat analysis, eight (57%), six (43%), and three (21%) of 14 patients achieved a maximal period of control of 180, 360, and 720 d, respectively, despite augmentation of HIV-specific CD4+ and CD8+ T cell responses. The magnitude of HIV-1-specific cellular immune responses before treatment interruption did not predict duration of viremia control. The small sample size and lack of concurrent untreated controls preclude assessment of possible clinical benefit despite failure to control viremia by study criteria. These data indicate that despite initial control of viremia, durable viral control to less than 5,000 RNA copies/ml plasma in patients following treated acute HIV-1 infection occurs infrequently. Determination of whether early treatment leads to overall clinical benefit will require a larger and randomized clinical trial. These data may be relevant to current efforts to develop an HIV-1 vaccine designed to retard disease progression rather than prevent infection since they indicate that durable maintenance of low-level viremia may be difficult to achieve.